Company intelligence / Profile preview

Emmyon, Inc.

Coralville, Iowa, United Statesemmyon.com ↗

Ownership: Private
Development stage: Commercial

Overview

Emmyon has identified and validated several small molecule candidates that inhibit skeletal muscle atrophy in mouse models. Some of these are being advanced toward pharmaceutical development for human patients and others are used in nutritional products. The company’s approach leverages mRNA expression signatures from human biopsies to guide compound discovery and mechanistic research

Therapeutic areas: EndocrinologyNeurology
Modalities: small molecules (including natural compounds such as ursolic acid and tomatidine)
Industry: Biotech

Drug pipeline

1 asset

tomatidine

Preclinical

Partnerships

NIH SBIR funding indicates collaboration with government research agencies

Beyond the preview

Go deeper on Emmyon, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emmyon, Inc..